Can Ozempic and Similar Drugs Help With Depression and Anxiety?
Yes. A large Swedish study of over 95,000 adults found that semaglutide, the active ingredient in Ozempic and Wegovy, was linked to a 42 percent lower risk of worsening mental illness in people who already had depression or anxiety.
This is one of the largest studies to date exploring whether GLP-1 receptor agonists, a class of drugs best known for treating diabetes and obesity, might also protect mental health. The findings suggest these medications could offer real psychiatric benefits that go well beyond blood sugar and weight control.
What the Data Show
Researchers followed 95,490 adults in Sweden who had been diagnosed with depression or anxiety before starting a GLP-1 receptor agonist. Using a within-individual design, each person served as their own control. This means the study compared mental health outcomes during periods when a person was on the medication versus when they were not.
Semaglutide stood out with the strongest results. People taking it had a 44 percent reduction in worsening depression and a 38 percent reduction in worsening anxiety. Perhaps most striking, semaglutide was linked to a 47 percent lower risk of developing substance use disorders. Liraglutide, an older GLP-1 drug, showed similar benefits but with smaller effect sizes across the board.
Dr. Kumar’s Take
I find this study particularly convincing because of its design. When each person acts as their own control, you remove a huge number of confounding factors like genetics, personality, and baseline health that can cloud other types of research. A 42 percent reduction in worsening mental illness is not a small number, and the fact that it held up across depression, anxiety, and substance use disorders makes it even more compelling.
That said, this is not a randomized controlled trial. We cannot say for certain that GLP-1 drugs directly caused these improvements. Weight loss, better blood sugar control, and reduced inflammation could all play a role. But the signal here is strong enough that I expect we will see targeted clinical trials in the near future.
How the Study Was Designed
This was a national cohort study using Swedish health registries, which are among the most complete in the world. Every adult in the country who had a prior diagnosis of depression or anxiety and then started a GLP-1 receptor agonist was included. The within-individual approach compared each person’s mental health outcomes during treated and untreated periods, controlling for factors that stay the same within a person over time. This design is stronger than simply comparing people who took the drug to people who did not.
Why This Matters for Mental Health Treatment
Depression and anxiety are among the most common health conditions worldwide, and many patients do not respond well to existing treatments. The idea that a medication already approved and widely prescribed for other conditions could also stabilize mental health is exciting. It opens the door to dual-benefit prescribing, where a single drug addresses both metabolic and psychiatric needs. For patients already taking semaglutide or liraglutide for weight management or diabetes, these findings offer reassurance that their mental health may benefit too.
Practical Takeaways
- If you are taking a GLP-1 medication like Ozempic or Wegovy and also managing depression or anxiety, talk to your doctor about monitoring your mental health, as you may experience unexpected improvements.
- Do not start or switch to a GLP-1 drug solely for mental health benefits, as these medications are currently approved only for diabetes and weight management.
- If you have both metabolic and mental health conditions, ask your provider whether a GLP-1 receptor agonist might address both, since the evidence for dual benefits is growing.
Related Studies and Research
You might also find these related articles helpful:
- Sea swimming as a novel intervention for depression and anxiety explores how cold water exposure may help mood disorders through different pathways.
- Over-the-counter products for depression, anxiety, and insomnia in older adults reviews non-prescription options for common mental health conditions.
- Sugary drinks linked to 34% higher anxiety risk in teens highlights the connection between diet and mental health.
- Teen cannabis use linked to higher risk of psychotic and mood disorders examines substance-related psychiatric risk factors in young people.
FAQs
How do GLP-1 receptor agonists work in the brain?
GLP-1 receptors are found not only in the gut and pancreas but also in several brain regions involved in mood, reward, and stress responses. When a drug like semaglutide activates these receptors, it may reduce inflammation in the brain, improve how neurons communicate, and help regulate the body’s stress response system. Researchers believe these effects could explain why people taking these drugs show fewer signs of worsening depression and anxiety, though the exact mechanisms are still being studied.
Does weight loss from these drugs explain the mental health benefits?
Weight loss can certainly improve mood and self-esteem, but this study’s design helps separate that question. Because each person served as their own control, many weight-related factors were already accounted for. The researchers also noted that the mental health benefits appeared relatively quickly, sometimes before major weight loss occurred. This suggests the drugs may have direct effects on brain chemistry that go beyond simply helping people lose weight.
Are GLP-1 drugs likely to be prescribed specifically for depression in the future?
It is too early to say, but the strength of this evidence will likely push researchers toward randomized controlled trials focused specifically on mental health outcomes. Before any drug can be prescribed for a new condition, it needs to go through clinical trials designed for that purpose. Several research groups are already planning or conducting such trials. If the results hold up, we could see GLP-1 drugs approved for psychiatric use within the next several years, but that process takes time and rigorous testing.
Bottom Line
This large Swedish study found that semaglutide was associated with a 42 percent lower risk of worsening mental illness in adults with depression or anxiety. The benefits extended across depression, anxiety, and substance use disorders, with the study’s strong within-individual design adding credibility to the findings. While these drugs are not yet approved for mental health treatment, the evidence is building that GLP-1 receptor agonists may offer meaningful psychiatric benefits alongside their metabolic effects.
